Medicare AdvantageDocumentationMedium impact
MA08.083m, Leuprolide (Camcevi™, Camcevi ETM®, Eligard®, Fensolvi®, Lupron Depot®)
Independence Blue Cross·Oncology, Urology, Endocrinology·Pharmacy
Effective date
Jul 13, 2026
We identified it
Jul 14, 2026
Summary
MA08.083m updates medical necessity criteria and medical coding requirements for leuprolide (Camcevi, Eligard, Fensolvi, Lupron Depot) effective immediately. The policy change affects how these medications are coded and billed under Medicare Advantage plans, requiring the billing team to review and implement updated medical necessity documentation and coding guidance.
Action Required
By July 13, 2026: Billing team must obtain and review the full policy text for MA08.083m leuprolide from the source URL to identify specific medical necessity criteria changes and coding updates. Coordinate with providers and clinical staff to implement new documentation requirements for all leuprolide prescriptions (Camcevi, Camcevi ETM, Eligard, Fensolvi, Lupron Depot). Update billing software rules and encounter templates to reflect new medical necessity criteria. Verify that all leuprolide claims submitted after the effective date comply with updated coding standards. Do not submit claims without confirming alignment with the new medical necessity criteria, as non-compliant claims may be denied.